Steven Seedhouse
Stock Analyst at Cantor Fitzgerald
(3.32)
# 1,011
Out of 5,146 analysts
168
Total ratings
45.78%
Success rate
3.2%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $24 → $26 | $7.90 | +229.11% | 2 | Oct 15, 2025 | |
| DNTH Dianthus Therapeutics | Reiterates: Outperform | $56 → $63 | $53.11 | +18.62% | 4 | Sep 9, 2025 | |
| KRRO Korro Bio | Maintains: Strong Buy | $153 → $147 | $12.17 | +1,107.89% | 3 | Aug 13, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $77 → $82 | $92.19 | -11.05% | 20 | Aug 7, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $15.36 | -34.90% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $28.00 | - | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.93 | +973.77% | 14 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $32.97 | +215.44% | 20 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $4.76 | +362.18% | 2 | Dec 11, 2024 | |
| PRQR ProQR Therapeutics | Upgrades: Strong Buy | $6 → $14 | $1.59 | +780.50% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $143.77 | -35.31% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $42.35 | +60.57% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $21.64 | +389.83% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $6.63 | +126.24% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $16.19 | +245.89% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $14.28 | +299.16% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $6.77 | +224.96% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.18 | +679.82% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $4.53 | +672.63% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $95.03 | -60.01% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $0.40 | +1,143.78% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $56.11 | -32.28% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $8.32 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.21 | - | 14 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.65 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $12.17 | +2,118.57% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $188.02 | - | 2 | Apr 23, 2020 |
BioCryst Pharmaceuticals
Oct 15, 2025
Maintains: Overweight
Price Target: $24 → $26
Current: $7.90
Upside: +229.11%
Dianthus Therapeutics
Sep 9, 2025
Reiterates: Outperform
Price Target: $56 → $63
Current: $53.11
Upside: +18.62%
Korro Bio
Aug 13, 2025
Maintains: Strong Buy
Price Target: $153 → $147
Current: $12.17
Upside: +1,107.89%
Mirum Pharmaceuticals
Aug 7, 2025
Maintains: Strong Buy
Price Target: $77 → $82
Current: $92.19
Upside: -11.05%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $15.36
Upside: -34.90%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $28.00
Upside: -
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.93
Upside: +973.77%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $32.97
Upside: +215.44%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $4.76
Upside: +362.18%
ProQR Therapeutics
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $1.59
Upside: +780.50%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $143.77
Upside: -35.31%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $42.35
Upside: +60.57%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $21.64
Upside: +389.83%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $6.63
Upside: +126.24%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $16.19
Upside: +245.89%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $14.28
Upside: +299.16%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $6.77
Upside: +224.96%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.18
Upside: +679.82%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $4.53
Upside: +672.63%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $95.03
Upside: -60.01%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $0.40
Upside: +1,143.78%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $56.11
Upside: -32.28%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $8.32
Upside: -
Aug 5, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $10.21
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $0.65
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $12.17
Upside: +2,118.57%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $188.02
Upside: -